Skip to main content

Table 1 Country-level estimates of the main aspects of ART rollout and pretreatment NNRTI resistance in southern Africa

From: Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study

Country Timing of ART rollout, year (95% CrI) Intensity of ART rollout, per year (95% CrI) NNRTI PDR in 2018 (%) (95% CrI) NNRTI PDR in 2018 unrelated to ART programmes (%) (95% CrI) Proportion of NNRTI PDR in 2018 unrelated to ART programmes (%) (95% CrI) Fragility index regarding NNRTI PDR of ART programmes (95% CrI)
Botswana 2005 (2004–2006) 0.13 (0.12–0.15) 3.7% (2.6–5.6) 1.5% (0.7–2.4) 42% (15–2) 0.01 (0.00–0.11)
Eswatini 2009 (2009–2009) 0.24 (0.18–0.29) 25.3% (17.9–33.7) 1.6% (0.5–3.0) 6% (2–14) 0.64 (0.23–11.8)
Lesotho 2007 (2006–2007) 0.09 (0.082–0.099) 3.9% (1.3–9.8) 2.2% (0.8–4.6) 62% (20–86) 0.01 (0.00–0.70)
Malawi 2009 (2009–2009) 0.22 (0.18–0.28) 8.9% (4.2–24.4) 3.2% (2.1–4.4) 37% (11–72) 0.04 (0.00–1.30)
Mozambique 2009 (2009–2009) 0.11 (0.094–0.13) 3.3% (1.9–6.9) 2.0% (1.2–3.0) 65% (26–84) 0.01 (0.00–0.70)
Namibia 2007 (2006–2008) 0.18 (0.15–0.21) 24.9% (17.8–32.2) 2.1% (0.8–4.7) 8% (3–22) 0.48 (0.15–11.2)
South Africa 2009 (2009–2009) 0.13 (0.12–0.14) 22.7% (18.9–26.1) 1.7% (1.3–2.3) 8% (5–10) 1.21 (0.83–9.84)
Zambia 2008 (2007–2009) 0.17 (0.14–0.21) 6.3% (3.5–13.5) 3.1% (2.1–4.4) 50% (21–80) 0.01 (0.00–0.27)
Zimbabwe 2009 (2009–2009) 0.25 (0.2–0.32) 13.7% (6.8–22.9) 3.9% (3.0–4.7) 28% (15–60) 0.17 (0.00–2.65)
  1. PDR pretreatment drug resistance
  2. The timing of ART rollout refers to the date at which 50% of the maximum treatment rate is reached. The intensity of ART rollout refers to the peak treatment rate per year. NNRTI PDR in 2018 is the model-predicted prevalence of NNRTI PDR. Posterior medians with 95% credibility intervals are shown